TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03063671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine, bupivacine,dexmedetomidine
Description: thoracic epidural catheter insertion at T4-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine, bupivacine,dexmedetomidine
Description: thoracic epidural catheter insertion at T4-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine, bupivacine,dexmedetomidine
Description: thoracic epidural catheter insertion at T4-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine, bupivacine,dexmedetomidine
Description: thoracic epidural catheter insertion at T4-5
Study: NCT03901456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care to Plan
Description: Care to Plan (CtP) is an online care planning tool that provides a succinct and clear overview of various types of ADRD caregiver interventions, administers a brief validated assessment of risk, and generates individualized service recommendations for Alzheimer's disease and related dementia (ADRD) caregivers as well as resources that link users to a selected recommendation. Caregivers will complete the tool with the guidance of a CtP interventionist (Senior Care Navigator/Riverside Health System staff). The interventionist will discuss CtP recommendations with caregivers and help caregivers enroll in a recommended support service if so desired.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care to Plan
Description: Care to Plan (CtP) is an online care planning tool that provides a succinct and clear overview of various types of ADRD caregiver interventions, administers a brief validated assessment of risk, and generates individualized service recommendations for Alzheimer's disease and related dementia (ADRD) caregivers as well as resources that link users to a selected recommendation. Caregivers will complete the tool with the guidance of a CtP interventionist (Senior Care Navigator/Riverside Health System staff). The interventionist will discuss CtP recommendations with caregivers and help caregivers enroll in a recommended support service if so desired.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Receive care as usual.~Note: If eligible, participants in this control group will be asked if they are interested in enrolling in a similar, additional feature of the study to test the Care to Plan tool following the initial 6-month study.
Study: NCT04447612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous infusion of durvalumab 1500mg every 4 weeks for 13 cycles (1 year), starting 1 week before start of induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction phase: cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles Concurrent phase: cisplatin 100mg/m2 starting on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Induction phase: cisplatin 100mg/m2 on day 1 via intravenous infusion every 3 weeks for 3 cycles Concurrent phase: cisplatin 100mg/m2 starting on day 1 of radiation therapy via intravenous infusion every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Induction phase: gemcitabine 1000mg/m2 on day 1 and day 8 via intravenous infusion every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Induction phase: gemcitabine 1000mg/m2 on day 1 and day 8 via intravenous infusion every 3 weeks for 3 cycles
Study: NCT01646060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CM-1500
Description: Blood Volume Monitor
Study: NCT02362412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: A tablet containing 50 mg or 150 mg of quetiapine taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: A tablet containing 50 mg or 150 mg of quetiapine taken orally.
Study: NCT00741962

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VR-3 Herbal Blend
Description: This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
Study: NCT00952627

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Description: 50 mg tablet, 200 mg/day, 4 tablets/day
Study: NCT05199155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NerVFIX
Description: Decellularized, freeze-dried and sterile allogeneic graft of artery or vein from umbilical cord use by the investigator as a nerve regeneration conduit
Study: NCT01278628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: exercise class once a year
Study: NCT05063383

Intervention type: OTHER
Intervention: This study does not involve any interventions
Description: This study does not involve any interventions

Intervention type: OTHER
Intervention: This study does not involve any interventions
Description: This study does not involve any interventions
Study: NCT03288025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Exercise
Description: 5 times a week exercise training and biweekly diet counseling for 12 weeks.
Study: NCT02617212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant surgery
Description: The volunteers will receive one or two dental implant(s) placed by a surgical procedure, under local anesthesia and careful soft and hard tissue handling. After implant insertion, the volunteers will be randomly assigned to one arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant surgery
Description: The volunteers will receive one or two dental implant(s) placed by a surgical procedure, under local anesthesia and careful soft and hard tissue handling. After implant insertion, the volunteers will be randomly assigned to one arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Three abutment dis-/reconnections.
Description: At the active comparator arm, each implant will receive a titanium healing abutment during the surgery, according to manufacturer's recommendations. Three dis-/reconnections of abutments will be performed after the soft tissue healing period: the first, after 8 weeks, for adjustment of the emergence profile by healing abutment changing; the second, 10 weeks after surgery, for intra-oral prosthetic abutment selection; and the third, 12 weeks after surgery, for the prosthetic abutment definitive connection with the manufacturer recommended torque.
Study: NCT01179763

Intervention type: OTHER
Intervention: Optical coherence tomography
Description: Spectral domain optical coherence tomography will be conducted once when patients are enrolled.
Study: NCT03186469

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Baby shower
Description: A Safety Baby Shower using didactic and experiential teaching methods to educate participants on safety topics focused on reducing infant mortality. Participants receive safety products as their shower gifts with education on appropriate use of the products. The relaxed setting also encourages participants to seek answers and clarify myths from credible sources not otherwise available among family and friends. For intervention provides information on the infant's sleep position, bedding, co-sleeping, and tobacco exposure, all of which, alone or in combination, are risk factors for sleep-related deaths in infants. Breastfeeding, a protective factor for SIDS, will be encouraged.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Baby shower
Description: A Safety Baby Shower using didactic and experiential teaching methods to educate participants on safety topics focused on reducing infant mortality. Participants receive safety products as their shower gifts with education on appropriate use of the products. The relaxed setting also encourages participants to seek answers and clarify myths from credible sources not otherwise available among family and friends. For intervention provides information on the infant's sleep position, bedding, co-sleeping, and tobacco exposure, all of which, alone or in combination, are risk factors for sleep-related deaths in infants. Breastfeeding, a protective factor for SIDS, will be encouraged.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: Participants will received standard of care in regards to infant injury prevention. Written material on car seat safety, prevention of abusive head trauma, and safe sleep environments will be provide to participants.
Study: NCT01977144

Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Chromosomal Screening
Study: NCT02558023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urapidil
Description: Urapidil (Eupressyl\*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicardipine
Description: Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1
Study: NCT03626415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
Study: NCT03232723

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole-cortex MEG System (with optional EEG)
Description: Whole-Cortex MEG System non- invasively measures the magnetoencephalographic (MEG) signals (and, optionally, electroencephalographic EEG signals) produced by electrically active tissue of the brain. These signals are recorded by a computerized data acquisition system, displayed, and may then be interpreted by trained physicians to help localize these active areas. The location may then be correlated with anatomical information of the brain. MEG is routinely used to identify the locations of visual, auditory, somatosensory, and motor cortex in the brain.
Study: NCT02958163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-arterial Chemo-Embolization
Description: Trans-Arterial Chemo-Embolization will be performed with Doxorubicin-Eluting-Beads (DEB-TACE). It will be performed in each arm of treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-arterial Chemo-Embolization
Description: Trans-Arterial Chemo-Embolization will be performed with Doxorubicin-Eluting-Beads (DEB-TACE). It will be performed in each arm of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: SABR schemes will be adapted according to the CP score and the vicinity of surrounding organs at risk. These are the different schemes proposed in this trial:~48Gy = 3x16Gy BED 124.8Gy ( α/β=10) 50Gy = 5x10Gy BED 100Gy ( α/β=10) 48Gy = 6x8Gy BED 86.4Gy ( α/β=10) 40Gy = 5x8Gy BED 72Gy ( α/β=10)~For patients with Child-Pugh (CP) A cirrhosis : the choice of the scheme will be left to each physician. The highest BED should be favored if dose constraints to the organs at risk are respected.~For patients with CP B cirrhosis : only the latter scheme will be allowed: 40Gy = 5x8Gy.
Study: NCT01801397

Intervention type: DRUG
Group type: OTHER
Intervention: osteoanabolic therapy
Study: NCT03756012

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algovita Spinal Cord Stimulation System
Description: The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algovita Spinal Cord Stimulation System
Description: The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
Study: NCT00952627

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01946906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Study: NCT02050932

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 60 mg Fe as FeSO4 with stable isotopic labels
Description: Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
Study: NCT04174963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eToke + TPsy
Description: Combination of brief computerized intervention (eToke) with Information-Motivation-Behavior based text messages tailored to young adults in psychiatric treatment
Study: NCT04312997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042 Inhalation Solution
Description: 20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
Study: NCT01804608

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor
Study: NCT02960295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-Self-monitoring of blood glucose
Description: Self-monitoring of blood glucose 4 times daily: fasting and 1-hour after each meal. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Intervention: At every office visit and at every telephone (virtual) visit the patient's physician will review glucose results and make adjustments in diet, activity, or medication to bring glucose into desired range.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-Self-weighing
Description: Self-weighing on electronic scale at least once a week. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Consultation with the nutritionist will be obtained for women gaining in excess of or less than that indicated for her pre-pregnancy BMI, per Institute of Medicine (IOM) standards.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3-Self-checking of blood pressure
Description: Self-checking of blood pressure at least weekly with sphygmomanometer. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Patients with elevated blood pressure will be requested to come to Obstetrics Triage immediately for further assessment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-Checking fetal heart rate
Description: Patient will record her fetus' heart rate with a Doppler device at least once weekly. The patient will immediately report to Labor and Delivery for any fetal heart rate below 100 beats per minute or greater than 160 beats per minute over a 10 minute observation period.Those reporting a fetal heart rate outside of the normal range will be requested to come to ObstetricTriage for further assessment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5-Visits with caregivers
Description: Telephone visits will alternate with in-office visits.Those failing to keep appointments will be contacted and reappointed at a mutually convenient time.
Study: NCT04613167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: The first group will receive alirocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: The second group will receive evolocumab. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control group
Description: The third group will receive only optimal guidelines-based secondary preventive treatment. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
Study: NCT01710748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polymer-Based Everolimus-Eluting Stent
Description: Polymer-Based Everolimus-Eluting Stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer-Free Amphilimus-Eluting Stent
Description: Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
Study: NCT03743974

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic shoulder surgery of rotary cuff (ISB)
Description: ISB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic shoulder surgery of rotary cuff (CSB)
Description: SCB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
Study: NCT00363077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1247446A Group
Description: Low dose influenza vaccine adjuvanted with AS03 compared

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.
Study: NCT04020458

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental intervention
Description: Dental intervention plan for Group 1 and 3 subjects with periodontitis only, i) Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental intervention
Description: Dental intervention plan for Group 1 and 3 subjects with periodontitis only, i) Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)
Study: NCT02617212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No abutment dis-/reconnections.
Description: Each experimental arm implant will receive its definitive prosthetic abutment at the surgical procedure. The manufacturer recommended torque will be applied so that no disconnection of the abutment will occur during and after completion of the treatment. The abutment will receive healing caps, which shall remain in position until the end of 12 weeks after surgery.
Study: NCT04312997

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline for inhalation
Study: NCT00625222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: 1mA, 15 Minutes, constant direct current
Study: NCT04918901

Intervention type: COMBINATION_PRODUCT
Intervention: NO Severe COVID-19
Description: Non-severe and critically ill patients with COVID-19
Study: NCT02484625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potato chips
Description: Commercially available potato chips, 180 kcal
Study: NCT03196284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concizumab
Description: A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concizumab
Description: A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase